Related Experiment Video

Updated: Jul 5, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

The use of insulin pump therapy in the pediatric age group

S Shalitin1, M Phillip

  • 1Jesse Z. and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center of Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.

Hormone Research
|May 22, 2008
PubMed

Insights

Continuous subcutaneous insulin infusion (CSII) helps manage blood glucose in diabetic children. While offering flexibility, CSII did not show significant HbA1c improvements compared to multiple daily injections in pediatric patients.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Diabetes Management

Background:

  • Managing blood glucose in children with diabetes is crucial for preventing long-term complications.
  • Continuous subcutaneous insulin infusion (CSII) is a treatment option for type 1 diabetes mellitus.
  • CSII aims to mimic physiological insulin secretion patterns.

Purpose of the Study:

  • To review the current use of CSII in pediatric and adolescent patients with type 1 diabetes.
  • To assess the effectiveness of CSII in managing blood glucose levels and preventing complications.

Main Methods:

  • Review of randomized crossover and controlled trials comparing CSII to multiple daily injections (MDI).
  • Focus on studies involving pediatric and adolescent populations with type 1 diabetes.
  • Analysis of outcomes related to glycemic control and hypoglycemia.

Main Results:

  • CSII provides a more physiological method of insulin delivery compared to MDI.
  • CSII offers greater flexibility and precision in insulin delivery.
  • Studies generally found no significant difference in HbA1c levels between CSII and MDI in children and adolescents.

Conclusions:

  • CSII is a viable treatment option for pediatric and adolescent type 1 diabetes.
  • While CSII may reduce severe hypoglycemia, it does not consistently improve HbA1c compared to MDI.
  • Further research may be needed to optimize CSII therapy in this population.

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...